Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Plus Pola-R-CHP in First-Line DLBCL
NCT07778212Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Complete Response Rate at 12 months, Objective Response Rate at 12 months and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07778212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778212.